Expanding medicines for neurologic disorders on the WHO Model List

A comparative analysis of the Libyan national essential medicines list and the WHO model list of essential medicines

AIM AND OBJECTIVES To examine the concordance of the Libyan Pharmaceutical List of Essential Medicines (LPLEM) with the World Health Organization Model List of Essential Medicines 2009 (WMLEM 2009). METHODS The concordance between generic medicines listed in the WMLEM 2009 (standard reference list) and the LPLEM 2006 (comparator list) was evaluated. RESULTS The total number of Basic Essenti...

WHO to launch first essential medicines list for children.

CAH COMMENTS - 2nd WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN

Background: Parental attitudes towards the use of inhaled therapy in children with chronic asthma influencetreatment adherence and outcome. In the present study, we evaluated the perceptions and concerns of parentsof children with chronic asthma towards inhaled therapy.Methods: A self-administered standard questionnaire was distributed to parents of children attending thePaediat...

Review Possible Deletion of Medroxyprogesterone from the 14th Who Model List of Essential Medicines

Background In 2004, WHO Pharmaceuticals Newsletter reported a Pfizer Canada advice originated by results of new clinical studies that suggest the association between use of medroxyprogesterone acetate suspension for injection and substantial loss in bone mineral density. The publication stressed: “The loss in bone density is greater with increasing duration of treatment. The loss in bone densit...

Adding a medicine to the WHO model list of essential medicines.

Although the concept of essential medicines is not new, the processes that lead to placement of these medicines on the World Health Organization Model List of Essential Medicines are not well understood. Here, we describe the process by which we added a class of drugs, statins, to the Model List to help combat the growing global epidemic of cardiovascular disease.